Replies to post #122912 on Cytodyn Inc (CYDY)

[Leronlimab4DaWin]

Special Kinda Dumb

1) DSMB will not approve EUA based on a hunch. FDA already rejected EUA based on CD10 trial results. Just like MHRA rejected fast-track based on CD10 (still no EU sites for CD12 btw)

2) Of Nader unblinds the data and takes the penalty, in order for it to have a p-value <0.045 the placebo death rate will need to be over 35%, which is extremely unlikely. If it doesn't have a better than 0.045 P-value this comment is moot bc the drug sucks

We are in a pandemic, people are going to want leronlimab even if the results are marginally good because it is so safe of a drug.